- $1.94bn
- $5.14bn
- $5.81bn
Brief: Chemours Co Board Increases From Ten To Eleven Members
Brief: The Chemours Company Announces Completion Of Euro Denominated Term Loan Repricing
Brief: The Chemours Company Announces Completion Of Private Offering Of $600,000,000 Aggregate Principal Amount Of 8.000% Senior Unsecured Notes Due 2033
Brief: The Chemours Company Announces Pricing Of Private Offering Of $600,000,000 Of 8.000% Senior Notes Due 2033
Brief: The Chemours Company Announces Private Offering Of $600,000,000 Of Senior Notes Due 2033
Chemours Co reports results for the quarter ended in September 30 - Earnings Summary
Chemours rises after Q3 profit beat
Brief: Chemours Q3 Adjusted EPS USD 0.4 Vs. IBES Estimate USD 0.28
RBC Capital Markets sees dour Q3 for chemical commodity companies
U.S. RESEARCH ROUNDUP- ANI Pharmaceuticals, Deere & Co, Zoetis
3M, Corteva, Chemours hit with class action over 'forever chemicals' in carpet
Brief: Soros Fund Management LLC Cuts Share Stake In Amazon, Raises In Astrazeneca Plc, American International Group
Brief: Chemours Opens State-Of-The-Art Battery Innovation Center
U.S. RESEARCH ROUNDUP-Airbnb, Dollar General, Walmart
U.S. RESEARCH ROUNDUP- Actinium Pharmaceuticals, Albemarle, ArcBest
Chemours Co reports results for the quarter ended in June - Earnings Summary
Brief: Chemours Q2 Adjusted EPS USD 0.38 Vs. IBES Estimate USD 0.57
Chemours Co expected to post earnings of 57 cents a share - Earnings Preview
Chemours' challenge to EPA PFAS advisory tossed by U.S. appeals court